Welcome to our dedicated page for ContraFect Corporation news (Ticker: CFRX), a resource for investors and traders seeking the latest updates and insights on ContraFect Corporation stock.
ContraFect Corporation (CFRX) maintains this comprehensive news hub for stakeholders tracking advancements in antimicrobial therapies. Our curated collection delivers essential updates on the biotechnology leader’s progress against drug-resistant infections through its pioneering lysin and monoclonal antibody platforms.
Access timely reports on clinical trial developments, regulatory milestones, and strategic collaborations shaping the future of hospital infection treatment. The resource serves investors and healthcare professionals alike with verified information about therapeutic candidates in development and their potential market impact.
Key updates include progress reports on antibacterial agents targeting multidrug-resistant organisms, financial disclosures demonstrating R&D commitment, and partnership announcements with research institutions. All content undergoes rigorous verification to ensure compliance with financial reporting standards.
Bookmark this page for streamlined monitoring of ContraFect’s scientific breakthroughs and corporate developments. For real-time alerts, consult the company’s official investor relations channels alongside this resource.
ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company, announced that CEO Roger Pomerantz will participate in a fireside chat at the Maxim Group 2022 Virtual Growth Conference from March 28–30, 2022. The chat, scheduled for March 28 at 2:00 PM ET, will be led by Jason McCarthy, Ph.D. Investors can register to view the talk here. ContraFect focuses on developing direct lytic agents (DLAs) to combat antibiotic-resistant infections, with a notable candidate, exebacase, undergoing pivotal Phase 3 trials.
ContraFect Corporation (Nasdaq: CFRX) announced that Dr. Roger Pomerantz, the company's President and CEO, will participate in a fireside chat at the SVB Leerink 11th Annual Global Healthcare Conference occurring virtually from February 14-18, 2022. The chat is scheduled for February 17, 2022, at 10:00 AM ET. Investors can access a live webcast on ContraFect's website, which will also be available as an archive for a limited time. The company focuses on developing direct lytic agents to combat antibiotic-resistant infections, addressing a critical public health challenge.
ContraFect Corporation (Nasdaq: CFRX) has received a new contract award from the Cystic Fibrosis Foundation to explore the utility of exebacase in treating MRSA lung infections in cystic fibrosis patients. This 12-month program will assess the in vitro activity of the drug against bacterial specimens from patients. The prevalence of MRSA in cystic fibrosis has increased significantly, presenting a critical health risk. ContraFect retains global rights to exebacase and its therapeutic pipeline, focusing on addressing the urgent needs of antibiotic-resistant infections.
ContraFect Corporation (Nasdaq: CFRX) announced a significant case report showcasing its investigational drug exebacase as a potential adjunctive therapy for severe MRSA infections in pediatric patients. Published in Clinical Infectious Diseases, the report details a case involving a 5-month-old infant with life-threatening MRSA bacteremia. Following standard treatments, the patient received exebacase under FDA authorization, leading to sterile blood cultures and clinical improvement. This single case suggests the need for further studies to assess exebacase's efficacy in treating MRSA in children.
ContraFect Corporation (CFRX) announced its third quarter 2021 financial results, reporting a net loss of $5.3 million, or $(0.13) per share, compared to a net income of $3.4 million, or $0.12 per share, in Q3 2020. R&D expenses rose to $8.7 million from $4.7 million year-over-year due to increased clinical study costs. The company continues to focus on its Phase 3 DISRUPT study for exebacase, which targets Staph aureus bloodstream infections, with nearly 60 active clinical sites. Interim analysis is anticipated in H1 2022.
ContraFect Corporation (Nasdaq: CFRX) announced promising data for its direct lytic agents, lysin CF-370 and amurin peptide AM1, which exhibit in vitro activity against prevalent Gram-negative pathogens linked to lung infections in cystic fibrosis patients. Presented at the North American Cystic Fibrosis Conference, these agents show potential efficacy against multi-drug resistant strains, including Pseudomonas aeruginosa. With limited existing treatment options, the results highlight the need for innovative therapies in this patient population.
ContraFect Corporation (Nasdaq: CFRX), a biotechnology company, announces a poster presentation at the North American Cystic Fibrosis Conference (NACFC) from November 2-5, 2021. The poster, titled 'Direct Lytic Agents (DLAs), a Novel Family of Antimicrobial Agents, Exert Potent in vitro Bactericidal Activity Against Gram-negative Pathogens', focuses on DLAs' effectiveness against pathogens causing pulmonary infections in Cystic Fibrosis patients. The presentation by Dr. Raymond Schuch will detail the promise of DLAs in combating antibiotic-resistant infections. The poster will later be available on their website.
ContraFect Corporation (Nasdaq:CFRX) announced promising Phase 2 results of exebacase for treating Staphylococcus aureus bacteremia, presented at IDWeek 2021. The data indicates that 94.3% of patients receiving exebacase alongside standard antibiotics experienced symptom resolution, compared to 87.9% in the control group. Median time to resolution was significantly reduced to 3 days from 6 days. Exebacase may serve as a new treatment modality for serious bloodstream infections, including MRSA, where current options are limited. The company is advancing to a pivotal Phase 3 trial for further evaluation.
ContraFect Corporation (CFRX) announced the presentation of positive clinical data on exebacase at IDWeek 2021. A completed Phase 2 study demonstrated that exebacase significantly improved clinical responder rates by nearly 43 percentage points compared to standard-of-care antibiotics for Staphylococcus aureus bacteremia. Additionally, exebacase showed a 21 percentage point reduction in 30-day mortality. Exebacase is currently under evaluation in the pivotal Phase 3 DISRUPT study, potentially establishing it as a first-in-class treatment for this serious condition.
ContraFect Corporation (Nasdaq: CFRX) has announced that CEO Roger Pomerantz will participate in a fireside chat at the Cantor Global Virtual Healthcare Conference from September 27 to 30, 2021, specifically on September 29 at 11:20 AM ET. The event will be webcast live and archived for later access on the company’s website. ContraFect is focused on developing direct lytic agents for treating antibiotic-resistant infections, targeting pathogens like MRSA and P. aeruginosa, with its lead candidate, exebacase, currently in late-stage clinical trials.
